Immunicom, Inc.

Robert Segal

Stephen Michael Prince

Amir Jafri

Steven Francis Josephs

Matthew Ong

Thomas Emanuel Ichim

David L Schlotterbeck

The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological 'blocking factors'. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

Increasing responses to checkpoint inhibitors by extracorporeal apheresis

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNF&#x3b1;. The system and method are useful for the treatment of different cancer types, stages and severity.

System and method for removal of immune inhibitors from biological fluids

Growing community of inventors

San Diego, CA, United States of America

Robert Segal